Intracranial delivery of synthetic mRNA to suppress glioblastoma.

Abstract

Owing to messenger RNA's unique biological advantages, it has received increasing attention to be used as a therapeutic, known as mRNA-based gene therapy. It is critical to have an ideal strategy of mRNA gene therapy for glioma, which grows in a special environment. In the present study, we screened out a safe and efficient transfection reagent for intracranial delivery of synthetic mRNA in mouse brain. First, in order to analyze the effect of different transfection reagents on the intracranial delivery of mRNA, the synthetic luciferase mRNA was wrapped with two different transfection reagents and microinjected into the brain at the fixed point. The expression status of delivered mRNA was monitored by a small animal imaging system. The possible reagent-induced biological toxicity was evaluated by behavioral and blood biochemical measurements. Then, to test the therapeutic effect of our intracranial delivery mRNA model on glioma, synthetic modified tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mRNA was used as an example of therapeutic application. This model demonstrated that synthetic mRNA could be successfully delivered into the brain using commercially available transfection reagents, and TransIT-mRNA showed better results than in vivo-jetPEI kit. This model can be applied in precise targeting and personalized gene therapy of glioma.

• Authors: Hao Peng, Xingrong Guo, Jinjuan He, Chao Duan, Minghuan Yang, Xianghua Zhang, Li Zhang, Rui Fu, Bin Wang, Dekang Wang, Hu Chen, Mengying Xie, Ping Feng, Longjun Dai, Xiangjun Tang, Jie Luo
• Journal: Molecular therapy oncolytics (Mol Ther Oncolytics) Vol. 24 Pg. 160-170 (Mar 17 2022) ISSN: 2372-7705 [Print] United States
• PMID: 35024442 (Publication Type: Journal Article)
• Copyright: © 2021 The Author(s).